Journal
OBESITY SURGERY
Volume 32, Issue 10, Pages 3481-3486Publisher
SPRINGER
DOI: 10.1007/s11695-022-06247-x
Keywords
Bariatric surgery; Sleeve gastrectomy; Oral drug absorption; Drug dissolution; Anticonvulsant agent; Therapeutic drug monitoring
Categories
Ask authors/readers for more resources
This study investigated the use of CBZ medication among patients undergoing bariatric surgery and found a decrease in CBZ levels post-surgery, with some patients experiencing significant worsening of their condition. Therefore, altered CBZ levels may occur for at least a year after bariatric surgery.
Bariatric surgery modifies the anatomy and physiology of the gastrointestinal tract. Carbamazepine (CBZ) is an anticonvulsant with multiple neuropsychiatric indications. Given CBZ physicochemical properties and narrow therapeutic index, bariatric surgery may potentially introduce clinically significant changes in CBZ oral absorption and bioavailability. In this communication, we describe eight patients undergoing sleeve gastrectomy (SG) and treated with CBZ, including therapeutic drug monitoring (TDM) and dosage adjustments at different timeframes before vs. after the surgery (< 3, 4-6, and 7-12 months post-SG), as well as clinical outcomes. We then provide a review of the available literature on CBZ therapy among bariatric patients, concluding with a mechanistic analysis of the results. Four of the eight patients presented with decreased post-SG CBZ levels, and two of them also experienced significant worsening of their previously well-controlled disease. Overall, altered CBZ levels are likely for at least a year after SG. Clinical recommendations include consultation with a clinical pharmacist, careful clinical monitoring, and periodic TDM after (vs. before) the bariatric surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available